News

The news comes after Nice approved the first long-term daily pill for endometriosis in March, known as relugolix combination therapy or Ryeqo. Helen Knight, director of medicines evaluation at Nice, ...
Ryeqo drug is hailed as a ‘potential step-change’ in how endometriosis is treated A new pill designed to transform the treatment of endometriosis has been approved for use on the NHS in ...
A new at-home daily pill for endometriosis has been approved for use on the NHS in England. The tablet, called linzagolix but ...
The new tablet, known as Ryeqo or relugolix-estradiol-norethisterone, has been approved to treat women of reproductive age for whom other treatment options – including medical and surgical ...
Ryeqo was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) last October based on results from the LIBERTY programme, consisting of two 24-week phase 3 clinical trials.
Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy after Gedeon Richter's Ryeqo was cleared for NHS use. This morning, NICE recommended ...